Erratum: A randomized, double-blind, placebocontrolled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation and Juan-Carlos Gomez 5
Correction
After the publication of this work [1], we became aware that it contains inaccurate description. The correct description on page 5 was "At every timepoint, statistically significant differences were observed between IM olanzapine and IM placebo groups (p < .01) (Figure one)", and not "At every timepoint, statistically significant differences were observed between IM olanzapine and IM placebo groups (p < .001) (Figure one)." We regret any inconvenience that this inaccuracy might have caused.
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